<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653848</url>
  </required_header>
  <id_info>
    <org_study_id>SPCG-13</org_study_id>
    <secondary_id>2006-001657-94</secondary_id>
    <nct_id>NCT00653848</nct_id>
  </id_info>
  <brief_title>Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy</brief_title>
  <acronym>AdRad</acronym>
  <official_title>Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-risk Prostate Cancer Treated With Radical Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scandinavian Prostate Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scandinavian Prostate Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour
      burden it should be effective in primarily treated intermediate and high risk prostate cancer
      as an adjuvant treatment after radiotherapy to prevent early relapse. This will therefore be
      tested in a randomised phase III trial where patients will be randomized either to docetaxel
      or surveillance
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint:

        -  PSA progression rate, ASTRO guidelines.

      Secondary endpoints:

        -  PSA doubling time after progression

        -  Quality of Life (QoL)

        -  Safety

        -  Metastases free survival

        -  Overall survival
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA progression rate</measure>
    <time_frame>From randomization to progression</time_frame>
    <description>According to RTOG-ASTRO guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA doubling time after progression, quality of life, safety, metastases free survival, overall survival</measure>
    <time_frame>From randomisation to year 2014</time_frame>
    <description>PSA doubling measured, FACT-P, detection of metastatic lesions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>six of docetaxel every third week + hormonal treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>hormonal treatment only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel 75 mg/square meter i.v. every third week, six cycles</description>
    <arm_group_label>Docetaxel arm</arm_group_label>
    <other_name>LHRH ananlog 9 months</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men &gt; 18 and â‰¤75 years of age.

          -  WHO/ECOG performance status 0 - 1.

          -  Histological proven adenocarcinoma of the prostate within 12 months prior to
             randomisation

          -  One of the following:

               -  T2 with Gleason score 7(4+3 ) and PSA &gt;10 ng/ml to &lt; 70 ng/ml

               -  T2 with Gleason 8-10, any PSA &lt; 70 ng/ml

               -  any T3 tumour

          -  Prior neoadjuvant hormone therapy is mandatory for all patients

          -  Adequate haematological-, liver- and kidney function. (Hemoglobin &gt; 110 g/l,
             neutrophils &gt; 1.5 x 109/ l, platelets &gt; 150 x 109/ l, ASAT and ALAT &lt; 1.5 x ULN, ALP &lt;
             1.5 x ULN, creatinine &lt; 1.5 x ULN)

          -  Written informed consent

        Exclusion Criteria:

          -  M+

          -  N+ clinical or pathological

          -  Patients with a history of previous malignant disease. Exceptions should be made for
             basal cell carcinoma (BCC) and squamous cell carcinoma of the skin. Exceptions should
             also be made for curatively treated malignant disease, which has been disease free for
             the past five years.

          -  Previous radiotherapy to the pelvic region.

          -  Previous chemotherapy within 5 years.

          -  Systemic corticosteroids within 6 months prior to randomisation.

          -  Unstable cardiovascular disease, including myocardial infarction, within 6 months
             prior to randomisation.

          -  Active untreated infectious disease, including tuberculosis, MRSA.

          -  Active gastric ulcer.

          -  Known hypersensitivity to Polysorbate 80 (an excipient of docetaxel)

          -  Other serious illness or medical condition
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirkko-Liisa i Kellokumpu-Lehtinen, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jon R Iversen</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvant treatment, high risk, radical radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

